SPOTLIGHT: Barr, Novartis in Ritalin LA patent fight

Barr Pharmaceuticals is challenging Novartis' patent on the attention deficit hyperactivity drug Ritalin LA, which sold $109 million worth in the U.S. for the year ending in August. The Swiss drug maker filed suit against Barr Friday, hoping to keep the generics firm from taking its version of the product to market. Report